Avidian Wealth Enterprises’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.91M Buy
79,424
+4,018
+5% +$105K 0.05% 219
2026
Q1
$2.12M Buy
75,406
+51,722
+218% +$1.38M 0.07% 182
2025
Q4
$590K Buy
23,684
+2,783
+13% +$70.2K 0.02% 342
2025
Q3
$533K Buy
20,901
+956
+5% +$23.6K 0.02% 356
2025
Q2
$483K Buy
19,945
+1,712
+9% +$39.9K 0.02% 341
2025
Q1
$462K Sell
18,233
-2,007
-10% -$52.5K 0.02% 323
2024
Q4
$537K Sell
20,240
-2,080
-9% -$56.4K 0.02% 284
2024
Q3
$646K Buy
22,320
+897
+4% +$26.2K 0.03% 254
2024
Q2
$599K Buy
21,423
+3,596
+20% +$99K 0.02% 256
2024
Q1
$495K Sell
17,827
-2,190
-11% -$60.8K 0.02% 266
2023
Q4
$576K Sell
20,017
-1,087
-5% -$32.9K 0.04% 240
2023
Q3
$700K Sell
21,104
-975
-4% -$34.5K 0.05% 201
2023
Q2
$810K Sell
22,079
-34,757
-61% -$1.35M 0.05% 210
2023
Q1
$2.32M Buy
56,836
+728
+1% +$31.4K 0.13% 132
2022
Q4
$2.87M Buy
56,108
+4,487
+9% +$215K 0.19% 98
2022
Q3
$2.26M Sell
51,621
-1,612
-3% -$78.3K 0.16% 88
2022
Q2
$2.79M Buy
53,233
+11,727
+28% +$598K 0.2% 88
2022
Q1
$2.15M Buy
41,506
+1,938
+5% +$101K 0.13% 113
2021
Q4
$2.34M Buy
39,568
+446
+1% +$22.1K 0.15% 110
2021
Q3
$1.68M Buy
39,122
+4,616
+13% +$204K 0.13% 95
2021
Q2
$1.35M Buy
34,506
+1,109
+3% +$43.1K 0.1% 109
2021
Q1
$1.21M Buy
33,397
+1,620
+5% +$57.5K 0.1% 109
2020
Q4
$1.17M Sell
31,777
-38
-0.1% -$1.39K 0.11% 103
2020
Q3
$1.11M Buy
31,815
+3,940
+14% +$138K 0.13% 99
2020
Q2
$865K Sell
27,875
-2,729
-9% -$92.7K 0.12% 99
2020
Q1
$948K Buy
30,604
+12,216
+66% +$416K 0.15% 75
2019
Q4
$684K Buy
18,388
+4,284
+30% +$153K 0.1% 90
2019
Q3
$481K Buy
14,104
+4,453
+46% +$162K 0.08% 103
2019
Q2
$397K Buy
9,651
+1,406
+17% +$55.8K 0.09% 79
2019
Q1
$332K Buy
8,245
+15
+0.2% +$601 0.07% 87
2018
Q4
$341K Buy
8,230
+2,542
+45% +$106K 0.12% 57
2018
Q3
$238K Buy
+5,688
New +$219K 0.07% 94

Other funds holding PFE

Avidian Wealth Enterprises's PFE Position: Q2 2026 in Review

Avidian Wealth Enterprises increased its Pfizer (PFE) stake by 5.3% in Q2 2026, buying an estimated $105K and bringing the position to 79,424 shares worth $1.91M. The position accounts for 0.05% of the portfolio, ranked #219.

Avidian Wealth Enterprises first reported a position in PFE in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.87M in Q4 2022. 2,824 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Avidian Wealth Enterprises held 79,424 shares of Pfizer worth $1.91M as of Q2 2026.
  • Avidian Wealth Enterprises bought 4,018 Pfizer shares in Q2 2026, an estimated $105K.
  • Pfizer made up 0.05% of Avidian Wealth Enterprises's portfolio in Q2 2026, its #219 holding.
  • Avidian Wealth Enterprises first reported a position in Pfizer in Q3 2018 and has held it in 32 quarters since.
  • Avidian Wealth Enterprises's Pfizer position peaked at $2.87M in Q4 2022.
  • 2,824 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Avidian Wealth Enterprises's 13F filing for Q2 2026, filed 24 Jul 2026.